Age-Related Macular Degeneration

Drs Eleonora M. Lad, David R. Lally, Jayanth Sridhar, and Nancy M. Holekamp share insights to ensure adherence to therapy once started.

An expert panel discusses the role of complement C3 vs C5 therapies and provides guidance for treatment selection in geographic atrophy.

The ERF and ERF-free groups had similar best visual acuity gains from baseline to week 52.

Drs Eleonora M. Lad and Nancy M. Holekamp review other emerging treatment options for geographic atrophy.

A panel of experts comments on the safety data of pegcetacoplan in geographic atrophy and their approach to monitoring patients.

A retrospective cohort analysis of patients in Finland show a notable overlap of the 2 forms of vision loss.

Eleonora M. Lad, MD, PhD, shares her approach to treating subfoveal lesions and geographic atrophy in both eyes.

Drs Eleonora M. Lad, David R. Lally, Jaynath R. Sridhar, and Nancy M. Holekamp discuss pegcetacoplan dose frequency in treating geographic atrophy.

Eyes with bacillary detachment had higher fluid volumes, increased CST, EZ attenuation, and increased sub-RPE volume at baseline.

Close to half of patients with wet AMD treated with aflibercept could safely stop eye injection therapy after one year without further vision loss, according to the pilot study.

A look back at 2022, including new drug approvals, the significance of treatment for geographic atrophy, and what the future holds within the retina space. Veeral Sheth, MD joins to discuss in a Q&A.

The results from the artificial intelligence deep learning model indicated alterations in the SD-OCT imaging regions attributed to the retinal nerve fiber and choroid layers.

A post-hoc analysis of the HARBOR trial suggest a greater proportion of ranibizumab-treated eyes with nAMD gained/maintained visual acuity at SRF resolution.

A panel of experts discuss clinical data with pegcetacoplan for treatment of geographic atrophy.

An expert panel provides an overview of pathophysiological changes in geographic atrophy, ongoing research and promising new treatment options.

Study data indicate the AI-based follow-up system could make an autonomous decision in 73% of the cases, of which 91.8% were in agreement with retina experts consensus.

No difference was seen in the odds of tractional retinal detachment between those with a loss to follow-up period of 6 months or longer and those without loss to follow-up.

The study data indicate high early-stage CRT variability showed a significantly higher risk of legal blindness.

The introduction of brolucizumab resulted in savings in the manufacturer-recommended and real-world evidence regimens.

Low luminance contrast sensitivity was significantly more reduced in nGA eyes than in eyes with drusen alone, but no differences were seen when assessing other cone functions with normal luminance CS or LLVA

Dry AMD was more common than wet AMD, but visual acuity was more significantly affected in patients with wet AMD.

The shared genetic structure and pleiotropic mechanisms in ocular diseases interprets their clinical associations to some extent, according to study authors.

The result show the gain in best-corrected visual acuity and the reduction in central subfield thickness at the conclusion of the core study was maintained up to week 24 of the extension study, with no differences in the safety profile.

Jaynath R. Sridhar, MD, shares insights into managing geographic atrophy in his clinic given that there is no FDA-approved treatment.

David R. Lally, MD, and Jayanth Sridhar, MD, comment on the use of imaging tools to for diagnosis and measuring progression of geographic atrophy.